Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CYC140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

Next Previous
Trial Profile

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CYC140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plogosertib (Primary)
  • Indications Adenoid cystic carcinoma; Advanced breast cancer; B-cell lymphoma; Biliary cancer; Bladder cancer; Colorectal cancer; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Liver cancer; Lung cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer; Small cell lung cancer; Solid tumours; T-cell lymphoma; Triple negative breast cancer
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Sponsors Cyclacel Pharmaceuticals

Most Recent Events

  • 13 Nov 2023 According to a Cyclacel Pharmaceuticals media release, the trial is recruiting patients at dose level 5.
  • 09 Nov 2022 According to a Cyclacel Pharmaceuticals media release, final data from dose escalation stage is expected in 2H 2023.
  • 09 Nov 2022 According to a Cyclacel Pharmaceuticals media release, interim data is expected in the first half of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top